July 2, 2026 – 8.45 am – Diagnostic Medical Systems (Euronext Growth Paris: FR0012202497 – ALDMS), a specialist in high-performance medical imaging systems for digital radiology and bone densitometry, communicates the half-year results of the liquidity contract entrusted by DMS Group to Natixis Oddo BHF dated May 7, 2025.

As of 30/06/2026, the following resources were included in the dedicated liquidity account:

• 162,636 shares
• €38,363

Over the period from 01/01/2026 to 30/06/2026 were executed:

• 751 purchase transactions
• 807 sale transactions

Over the same period, the volumes traded represented:

• 209,911 shares on purchase, representing €274,416
• 157,905 shares for sale, representing €210,429

It should be noted that when the contract was set up, the following resources were included in the dedicated liquidity account:

• 150,000 shares
• €50,000

UPCOMING EVENTS^*

• 20/07/2026 Q2 2026 Revenue
• 15/09/2026 2026 H1 Results

The publications will take place after the close of the Euronext market in Paris.
*Provisional schedule subject to change. Visit the DMS Group website.

Find financial information on our investor area: www.dms.com

Receive free financial information from DMS Group by registering on www.actusnews.com

ABOUT DMS GROUP
DMS Group is a French digital radiology manufacturer, internationally oriented, recognized as a key player and a key partner in the value chain, both for the quality of its solutions, and for its flexibility, ingenuity and responsible values.
In 2025, DMS Group achieved a consolidated revenue of €50 million, more than 80% of which was international, with a presence on all continents through a network of more than 140 national distributors.
DMS Group is listed on the Euronext Growth Paris market (ISIN: FR0012202497 - ticker: ALDMS) and is eligible for the PEA PME-ETI.
DMS Group is part of the ETIncelles program for SMEs that have the ambition and the desire to become mid-caps.